The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic ...

"Schizophrenia is a leading cause of disability worldwide ... People "are a little wary of claims before they actually see ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by Bristol Myers Squibb will be called ...

“Schizophrenia is a leading cause of disability ... little wary of claims before they actually see what happens with the drugs," Rind told The New York Times. He wondered about the potential ...